Meet the CRISPRMED24 Speakers - What will they talk about?

Meet the CRISPRMED24 Speakers:

1. Alessia Cavazza -?Preclinical development of gene editing therapies
2. Alexandra Madsen - Evaluation of CRISPR off-targets in single cells reveals previously unidentified off-targets and gives mechanistic insights in relation to cellular chromatin and gene expression state
3. Andre Cohnen - Improved synthetic RNA-guided nucleases for human therapeutic use
4. Andrew Bellinger -?Reinventing Cardiovascular Disease Treatment with Single-Course Gene Editing Medicines
5. Angelo Lombardo -?Exploiting Targeted Epigenome Editing for Therapeutic Applications
6. Anna Cereseto -?Identification and evolution of novel CRISPR-Cas9 systems from the human microbiome
7. Antonio Casini -?A novel portfolio approach to CRISPR-based gene therapies with tailored advantages for human therapeutics
8. Ashley Jacobi - End-to-End Tools for Interrogation of CRISPR-Cas Associated Genotoxicity
9. Avencia Sanchez-Mejías?- FiCAT gene writing platform for advanced therapies
10. Ayal Hendel -?Find-and-replace CRISPR Genome Editing HDR2.0:? a Promising Therapeutic Strategy
11. Ben Kleinstiver -?Engineered CRISPR Technologies to Improve Genome Editing
12. Bernhard Schmierer -?CRISPR functional genomics as a tool in drug discovery
13. Christian Groendahl - Pioneering precision medicines using microbial CRISPR gene therapy
14. Daniel Schraivogel -?With technology to biology: The single-cell functional genomics revolution
15. Duran Sürün - CRISPR associated substrate-linked directed evolution (CaSLiDE) for evolving highly efficient and specific miniature CRISPR-Cas systems
16. Fan Zhou -?Novel DNA Payloads and One-Stop CRISPR Toolbox Accelerate Non-Viral Gene Editing Therapeutics Development
17. Fiona?Behan -?Identification of novel oncology targets using a combination of functional genomics approaches & machine learning tools
18. Giulia Hardouin - Base editing mediated correction of severe β0 thalassemia mutations
19. Howard Wu -?Less is More: Efficient Novel Non-Viral Immune Cell Engineering With Precise Genomic Integration
20. Jan?Nelis - Project Delta Force - Upregulating delta globin as a new avenue to treat hemoglobinopathies
21. Jan Gorodkin -?Computational CRISPR/Cas9 gRNA design
22. Jin Chen - Functional genomics tools to dissect genetic networks of rejuvenation
23. Julien Valton -?From Allogeneic CAR-T Cells to SMART-CART to Fight Solid Tumors
24. Karim? Benabdellah El Khlanji - Connecting Innovators: CA21113 2nd Year Journey in Fostering Collaborative Networks for Breakthroughs in Genome Editing to Treat Human Diseases (GenE-Humdi COST action)
25. Karina Thorn - Transforming gene therapy from the few to the many
26. Kelly Banas - The Indel Code and its relevance to clinical development of CRISPR-directed gene editing in cancer
27. Kevin Holden?- Enabling GMP Production of sgRNA for CRISPR-based Cell and Gene Therapies
28. Kevin Luk - CRISPR/Cas9-mediated gene editing delivered by a single AAV vector inhibits viral reactivation of HSV-1 in a latent rabbit keratitis model
29. Laura? Sepp-Lorenzino - Realizing the Promise of CRISPR Therapeutics
30. Laura Torella - Investigating the interplay between CRISPR-induced double-strand breaks and recombinant AAV Integration in vivo
31. Luigi Naldini - Precision Genetic Engineering of Hematopoiesis by Gene Editing Tools (Keynote Lecture)
32. Maaike De Cock - CD4 T cell targeting lipid nanoparticles in the search for a genetic HIV cure
33. Madelynn Whittaker - In vivo correction of human phenylketonuria variants via prime editing and base editing: A gateway to equitable treatment of inborn errors of metabolism
34. Manuel Kaulich - "PRCISR CRISPR: How prior knowledge can drive hit confidence in perturbation genomics
35. Manuel Rhiel - Base editors provoke non-predictable chromosomal translocations and off-target editing
36. Marcello Maresca -?Pharmacological Interventions to Enhance Genome Editing Precision
37. Maria Silvia Roman Azcona - Epigenome editing as a novel and safe strategy to control multiple immune checkpoints expression in CAR T cells
38. Marianne Carlon - Base and prime editing strategies to re-write CFTR mutations causing cystic fibrosis - validation in patient derived cell models
39. Nikhil Gupta - Advancing Oncology Drug Discovery through Pooled CRISPR Screening
40. Nutsa Burduli - Genome-wide CRISPR-Cas9 screen for the elucidation of novel mediators of cytotoxicity and cytokine production in natural killer cells
41. Paul Diehl -?Flexible and Scalable Genetic Screens for Discovery and Characterization of Novel Therapeutic Targets
42. Paula M. Cevaal - Lipid nanoparticle delivery of dCas9-SAM to primary T-cells: towards a CRISPR activation-based therapeutic to cure HIV
43. Paula Rio?- Implementation of gene editing to correct hematopoietic stem cells from Fanconi anemia patients
44. Pia Johansson - CRISPR and human induced pluripotent stem cells - the magic duo for medical research
45. Raoul Hennig -?Charting New Horizons in guide RNA Manufacturing
46. Rasmus? O. Bak?- Genetic and transcriptional engineering of primary human blood cells?
47. Roberto Nitsch - Deciphering Cas9 immunogenicity
48. Samantha Maragh?- Updated outcomes of variant detection and quantitation from the first NIST Genome Editing Consortium Interlab Study
49. Saumyaa Saumyaa - Novel tools for Gene and Cell Therapy safety: Optical long-read genomics for detection and characterization of on- and off-target transgene integrations and off-target structural variants
50. Seung Wook?Yang -?CRISPR-Based Functional Genomic Characterization of Mechanisms of Action of Degraders for Targeted Protein Degradation
51. Sidsel Alsing -?Xdrop?: changing the approach to gene editing validation and single-cell functional assays
52. Simon Reed?- INDUCE-seq: Ensuring the safe development of cell and gene therapies by gene editing
53. Simone Spuler?- Precisely edited primary human muscle stem cells as an ATMP in muscular dystrophies
54. Stefanie Müthel - Cas9-mediated precise and template-free gene editing of a muscular dystrophy founder mutation: From single editing and off-target analysis to double editing and clinical translation
55. Stefano Stella?- Base editing based on Cas12a variants
56. Taejoon Kwon - Precision targeting tumor cells using cancer-specific genetic alterations with CRISPR/Cas
57. Thomas W. Skov - Efficient rAAV6-mediated HDR with low toxicity as a therapy for GATA2 deficiency through allele-specific gene correction in hematopoietic stem cells
58. Toni Cathomen -?New insights into on- and off-target effects of genome editing tools
59. Vasileios Georgakakos - Clean Cells Karyotyping and FISH assays as tools to evaluate the genetic stability of Cell therapy products - A decade of GMP experience
60. Waseem Qasim -?Genome edited therapeutic T cells
61. Xavier Duportet?- Translating in vivo gene editing to the Microbiome
62. Xiaoxia Cui? - Efficient large knockins in mice and cells validated using an all-in-one, multiplexed long-read sequencing assay?
63. Xinlai? Cheng - Revolutionizing CRISPR/Cas9 Gene Therapy with Targeted Chemical Modulation
64. Yonglun Luo? - Advancing CRISPR medicine by probing the detection, design, and delivery?
65. Ziyi Sheng - Integrating RNA structure and attention mechanisms for accurate CRISPR-Cas12a system gRNA efficiency prediction
66. Zhenya Ivakine? Deciphering the code of cancer: A deep dive into variants with saturation prime editing
67. Benchling - TBD

Check out the full CRISPRMED24 Program here.

Who will you meet at CRISPRMED24?

More than 300 scientists will attend CRISPRMED24. Check out the confirmed companies and organisations you will meet right here.

Registration is still open

Please register here if you would like to secure your pass before the registration deadline. All registrants will also get on-demand access to the presentations after the conference.

Sponsors, Exhibitors and Supporters

Remember to follow the ongoing Clinical Trials using a Gene Editing Tool here